Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?

abstract：:Up to 10% of the adult population in most countries may be affected by chronic bronchitis or chronic obstructive pulmonary disease. The course of the disease is characterized by frequent exacerbations with increased respiratory symptoms. Exacerbations are the most important cause of morbidity and mortality, and signif...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Miravitlles M

更新日期：2005-08-01 00:00:00

abstract：:Despite the intense debates over state or private sector dominance in healthcare finance and provision, there are no clear winners. Failed models exist on either end of the ideological spectrum and no country in the world has one that is purely public or purely private. Neither does a perfect public-private mix exist;...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lim MK

更新日期：2006-12-01 00:00:00

abstract：INTRODUCTION:Pharmacogenomic testing has the potential to greatly benefit patients by enabling personalization of medication management, ensuring better efficacy and decreasing the risk of side effects. However, to fully realize the potential of pharmacogenomic testing, there are several important issues that must be a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Moyer AM,Caraballo PJ

更新日期：2017-12-01 00:00:00

abstract：:Given the lack of evidence from randomized controlled trials and large prospective studies, controversy exists regarding the optimal treatment strategy for early stage prostate cancer. The impact of various treatments on health-related quality of life has become an increasingly important but controversial issue. The l...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： D'haese S,Bottomley A

更新日期：2004-06-01 00:00:00

abstract：:Differential item functioning (DIF) analyses are used to determine whether certain groups respond differently to a particular item of a test or questionnaire; however, these do not explain the reasons for observed response differences. Many studies have used external reviews of items, sometimes using blinded reviewers...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Scott NW,Fayers PM,Aaronson NK,Bottomley A,de Graeff A,Groenvold M,Gundy C,Koller M,Petersen MA,Sprangers MA,EORTC Quality of Life Group.,Quality of Life Cross-Cultural Meta-Analysis Group.

更新日期：2010-06-01 00:00:00

abstract：AIMS:To estimate the direct and indirect costs associated with disability due to multiple sclerosis (MS) in Poland. METHODS:Recently a cost-of-illness study was conducted in the Czech Republic, involving 909 patients with different levels of disability (the COMS study). Data on resource use from this trial was extrapo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Szmurło D,Fundament T,Ziobro M,Kruntorádová K,Doležal T,Głogowski C

更新日期：2014-06-01 00:00:00

abstract：:In this special report, the economics of prior authorization is examined with a focus on the break-even rate that requests are denied. Using a simple theoretical model, comparative static results are derived and used to consider the cost-effectiveness implications of future changes in prior authorization policies. ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Grant WC,Yoder DM,Mullins CD

更新日期：2004-04-01 00:00:00

abstract：:Everybody acknowledges the merits of the European Medicines Evaluation Agency and the progress the European system has permitted in evaluating and approving medicinal products. Nevertheless, the system established in 1995 is ripe for updating and improvement in the light of experience. Some limitations of the procedur...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Garattini S,Bertele' V

更新日期：2002-02-01 00:00:00

abstract：:The Resonance metallic stent is a new wire-based ureteral stent that was initially developed for patients with malignant ureteral obstruction. Potential advantages over traditional stents include resistance to encrustation and to external compression, allowing for increased dwell times and the maintenance of upper tra...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Polcari AJ,Hugen CM,López-Huertas HL,Turk TM

更新日期：2010-02-01 00:00:00

abstract：:Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Breau LM

更新日期：2003-06-01 00:00:00

abstract：:Quality of life has become an important end point in clinical trials and academic studies. The questionnaires developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group are widely used to measure quality of life in cancer patients. The expanding geographical coverage of current s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuliś D,Arnott M,Greimel ER,Bottomley A,Koller M,European Organisation for Research and Treatment of Cancer Quality of Life Group.

更新日期：2011-06-01 00:00:00

abstract：:Health technology assessment (HTA) has become an integral part of decision-making on the coverage of new health technologies in most health systems in the developed world. In recent years, pressure to involve patients and members of the public in HTA has grown. In this article, we summarize findings from peer-reviewed...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Menon D,Stafinski T

更新日期：2011-02-01 00:00:00

abstract：:Quality-adjusted life-years (QALYs) play an important role in reimbursement decisions when one of the criteria is the cost-effectiveness of the health technology. While for many generic QALYs (e.g., based on the EQ-5D) are viewed as the gold standard, there has been a considerable increase in interest in using conditi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrillo J,Cairns J

更新日期：2008-10-01 00:00:00

abstract：:A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Shepherd J,Jones J

更新日期：2007-12-01 00:00:00

abstract：:The European Organisation for Research and Treatment of Cancer (EORTC) 50th Anniversary Conference was held on the 15-16 March in Brussels, Belgium. More than 1100 participants (including EORTC members and staff, national research organizations, health authorities, patient advocacy groups, European Commission, cancer ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bean J,Bottomley A,Meunier F

更新日期：2012-08-01 00:00:00

abstract：:By 2018, Medicare payments will be tied to quality of care. The Centers for Medicare and Medicaid Services currently use quality-based metric for some reimbursements through their different programs. Existing and future quality metrics will rely on risk adjustment to avoid unfairly punishing those who see the sickest,...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Al Kazzi ES,Hutfless S

更新日期：2015-01-01 00:00:00

abstract：:Social Security Disability Insurance provides cash benefits to disabled workers and certain others under the age of 65 years. These individuals become eligible for Medicare 24 months after Social Security Disability Insurance cash benefits start. In 2001, 13.9% of Medicare's approximately 40 million beneficiaries were...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Iezzoni LI

更新日期：2006-06-01 00:00:00

abstract：:This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Thavarajah N,Chen E,Zeng L,Bedard G,Di Giovanni J,Lemke M,Lauzon N,Zhou M,Chu D,Chow E

更新日期：2012-10-01 00:00:00

abstract：:Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no internationa...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hirsch EB,Tam VH

更新日期：2010-08-01 00:00:00

abstract：AIM:To evaluate patient perception of the onset of action and overall satisfaction with a fast-dissolving tablet (FDT) formulation of ebastine in patients with intermittent or persistent allergic rhinitis. PATIENTS AND METHODS:This was a cross-sectional, multicenter, pharmacy-based survey involving adult patients (>18...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Roger A,Fortea J,Mora S,Artés M

更新日期：2008-08-01 00:00:00

abstract：:The 15th International Symposium for Health Information Management Research (ISHIMR) was organized jointly by University Hospital Zurich (Switzerland), the University of St Gallen (St Gallen, Switzerland) and the University of Sheffield (Sheffield, UK). Participants included researchers, healthcare professionals, heal...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bath PA,Sen BA,Raptis DA,Mettler T

更新日期：2012-02-01 00:00:00

abstract：AIMS:To quantify the relationship between the timing of gastroesophageal reflux disease (GERD) symptoms and the burden of illness. PATIENTS & METHODS:Data from the 2010 National Health and Wellness Survey were used. Regression analyses compared non-GERD controls with GERD patients with diurnal symptoms, nocturnal symp...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wagner JS,DiBonaventura MD,Balu S,Buchner D

更新日期：2011-12-01 00:00:00

abstract：:We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Neumann PJ,Saret CJ

更新日期：2013-10-01 00:00:00

abstract：:Osteoporosis is a public health threat to approximately 44 million individuals in the USA, or 55% of men and women over the age of 50 years. The primary goal of osteoporosis management is to prevent fracture, the most devastating consequence. Risk factors and bone mineral density can be assessed to determine appropria...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hansen LB

更新日期：2006-10-01 00:00:00

abstract：:Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sankaranarayanan J,Reardon T,Olsen KM

更新日期：2014-10-01 00:00:00

abstract：:A comprehensive literature search identified seven instruments, of which three had psychometric data available. These were the 'Sawicki instrument', the Duke Anticoagulation Satisfaction Scale (DASS) and Deep Vein Thrombosis Quality of Life (DVTQoL). Sawicki assessed five domains with acceptable internal reliability. ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wild D,Murray M,Shakespeare A,Reaney M,von Maltzahn R

更新日期：2008-06-01 00:00:00

abstract：:Ankylosing spondylitis (AS) is a complex systemic rheumatological disease which often causes severe disability and impaired quality of life (QoL). We searched the PubMed/MEDLINE electronic database for available literature on QoL and its predictors in patients with AS. Recent evidence indicates that AS patients have p...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kotsis K,Voulgari PV,Drosos AA,Carvalho AF,Hyphantis T

更新日期：2014-12-01 00:00:00

abstract：:This review was designed to explore and review the range of patient-reported outcomes used to assess people with epilepsy. Literature searches were conducted through EMBASE.com and supplemented with hand searching of relevant articles. References obtained through hand searches were compared with EMBASE.com citations u...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Stafford M,Gavriel S,Lloyd A

更新日期：2007-08-01 00:00:00

abstract：:At least 14% of cancer patients live with minor children. Being a parent with cancer has far-reaching consequences for individual treatment decision-making and quality of life in patients and their families. Even though the majority of children and adolescents do not show clinically relevant symptoms of psychopatholog...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Krauel K,Simon A,Krause-Hebecker N,Czimbalmos A,Bottomley A,Flechtner H

更新日期：2012-12-01 00:00:00

abstract：:Adenosine and dipyridamole are coronary vasodilators used in nuclear imaging. The acquisition cost of adenosine is four to ten times higher than dipyridamole. Data suggest comparable sensitivity, although specificity may be lower with dipyridamole. While side effect profiles are similar, fewer patients who receive ade...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Reddy P

更新日期：2002-12-01 00:00:00